A. Jeng

Hepatitis B core-related antigen (HBcrAg): an alternative to HBV DNA to assess treatment eligibility in Africa.

Maimuna Mendy, U. d’Alessandro, M. Thursz, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Screen and treat as an intervention programme for hepatitis B virus infection in 1 sub-Saharan Africa: the PROLIFICA experience in The Gambia

Taal, H. Whittle, S. Taylor-Robinson, 2016 .

Implementation of an in‐house quantitative real‐time polymerase chain reaction method for Hepatitis B virus quantification in West African countries

Maimuna Mendy, F. Zoulim, S. Mboup, 2016, Journal of viral hepatitis.

Correction: Protein Profiling in Hepatocellular Carcinoma by Label-Free Quantitative Proteomics in Two West African Populations

P. Hainaut, S. Taylor-Robinson, B. Kessler, 2013, PLoS ONE.

Protein Profiling in Hepatocellular Carcinoma by Label-Free Quantitative Proteomics in Two West African Populations

P. Hainaut, S. Taylor-Robinson, André Nogueira da Costa, 2013, PloS one.

Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians

S. Rowland-Jones, H. Whittle, A. Hall, 2010, Virology Journal.

Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa.

U. d’Alessandro, M. Thursz, I. Chemin, 2018, Journal of hepatology.

Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study.

H. Whittle, S. Taylor-Robinson, U. d’Alessandro, 2016, The Lancet. Global health.